Recevez les dernières nouvelles sur l'action Orchestra BioMed Hldgs avec des mises à jour sur les tendances du marché, les données financières et les analyses de Benzinga. Restez informé des performances de OBIO

Dernières nouvelles pour

ORCHESTRA BIOMED HOLDINGS IN

Orchestra BioMed Hldgs

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

Orchestra BioMed Holdings Inc

News

Health Care

Financing

Press Releases

General

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

Orchestra BioMed Announces Proposed Public Offering

IPOs

Orchestra BioMed Announces Pricing of $40 Million Public Offering

Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

Earnings

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction

Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology

Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout

Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit

LGND

OBIO

Accuray

Anteris Technologies Global Corp. - Common Stock

Anteris Technologies Glb

BrainsWay Ltd. - American Depositary Shares

BrainsWay

CapsoVision

CVRx

Electromed

Fractyl Health

Vyome Holdings

Inogen

KORU Medical Systems, Inc. - Common Stock

KORU Medical Systems

LENSAR

Lucid Diagnostics

Microbot Medical

Nyxoah

Outset Medical

Owlet

Profound Medical

Sight Sciences

Shoulder Innovations

SANUWAVE Health

Streamex

Neuronetics

Stereotaxis

Tactile Systems Technology, Inc. - Common Stock

Tactile Systems Tech

USBC

HC Wainwright & Co.

Chardan Capital

Barclays

B. Riley Securities

Jefferies

Comments

Orchestra BioMed Hldgs Actualités boursières

Actualités

Dernières nouvelles pour

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL